Sharechat Logo

Daily ShareChat: Tower

By Jenny Ruth

Monday 22nd June 2009

Text too small?
 Jenny Ruth

Tower's general insurance business was a stand-out performer in the six months ended March, according to Morningstar.

The general insurance business' net profit grew 22%, driven by strong growth in premiums and cost control.

"Underwriting growth was even stronger at 37% but this was offset by lower investment returns due adverse market conditions," Morningstar says.

"We think management has executed well so far in getting the business back on track. The firm sees scope for further price increases going forward which should be positive from a profitability perspective."

Tower's individual life business also did very well and gained market share, it says. Good cost control, particularly in funds management, was another highlight and further savings are expected in the second half.

"However, the health business witnessed a slowdown because of recessionary conditions as it is considered a discretionary product," Morningstar says.

Overall, Tower's net profit rose 32% to $26.6 million for the six months with underlying profit, excluding $5.1 million in one-off gains in the life business, grew 5%. Return on equity rose to 17.7% from 15.4% while gearing fell to 3.9% from 9%.

Morningstar is forecasting a $42 million net profit for the full year followed by a $45 million net profit next year.

 

BROKER CALL:  Morningstar rate Tower Limited (NZX: TWR ) as accumulate (downgraded from buy).

 

 

 

 



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Tower to return 'initial' $70M of capital from sale of life business
Tower shares fall to 2-month low as licensing requirements may weigh on capital returns
Tower's licensing talks with RBNZ may push up minimum solvency requirements
Tower names Hancock as new chief executive, replacing Flannagan
Tower posts first-half profit as asset sales reap gains of $51.4 mln
Fidelity Life acquires most of Tower's life insurance business
Flannagan to leave Tower after strategic review, asset sales
Tower FY profit jumps 67%, to return $120M to shareholders; shares jump
Tower sells medical insurance unit to nib for $102M
Stiassny joins Tower board as questions linger over strategy